154 related articles for article (PubMed ID: 30570412)
1. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract][Full Text] [Related]
2. The role of biomarkers in the management of bone-homing malignancies.
D'Oronzo S; Brown J; Coleman R
J Bone Oncol; 2017 Nov; 9():1-9. PubMed ID: 28948139
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.
Stamatopoulos A; Stamatopoulos T; Gamie Z; Kenanidis E; Ribeiro RDC; Rankin KS; Gerrand C; Dalgarno K; Tsiridis E
J Bone Oncol; 2019 Jun; 16():100231. PubMed ID: 30956944
[TBL] [Abstract][Full Text] [Related]
4. Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art.
Gentile M; Centonza A; Lovero D; Palmirotta R; Porta C; Silvestris F; D'Oronzo S
J Bone Oncol; 2021 Feb; 26():100337. PubMed ID: 33240786
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.
Chai X; Yinwang E; Wang Z; Wang Z; Xue Y; Li B; Zhou H; Zhang W; Wang S; Zhang Y; Li H; Mou H; Sun L; Qu H; Wang F; Zhang Z; Chen T; Ye Z
Front Oncol; 2021; 11():692788. PubMed ID: 34722241
[TBL] [Abstract][Full Text] [Related]
7. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
[TBL] [Abstract][Full Text] [Related]
8. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
D'Oronzo S; Coleman R; Brown J; Silvestris F
J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
[TBL] [Abstract][Full Text] [Related]
9. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
10. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
12. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
[TBL] [Abstract][Full Text] [Related]
13. Radiomics analysis of pre-treatment [
van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
[TBL] [Abstract][Full Text] [Related]
14. Role of multi-modality functional imaging in differentiation between benign and malignant thyroid
Shi H; Yuan Z; Yang C; Zhang J; Liu C; Sun J; Ye X
Clin Transl Oncol; 2019 Nov; 21(11):1561-1567. PubMed ID: 30924093
[TBL] [Abstract][Full Text] [Related]
15. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
[TBL] [Abstract][Full Text] [Related]
16. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
[TBL] [Abstract][Full Text] [Related]
17. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography.
Wu X; Kellokumpu-Lehtinen PL; Pertovaara H; Korkola P; Soimakallio S; Eskola H; Dastidar P
NMR Biomed; 2011 Dec; 24(10):1181-90. PubMed ID: 21387451
[TBL] [Abstract][Full Text] [Related]
18. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
19. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
20. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]